The goal of this observational study is to learn about the correlation between COVID-19 and hyperthyroidism in Patients with hyperthyroidism complicated with COVID-19. The main questions it aims to answer are： * The main research object is Graves disease (GD) patients. * Changes of hyperthyroidism in GD patients complicated with COVID-19 * Changes of anxiety and depression in GD patients before and after SARS-CoV-2 infection. * The effect of psychological intervention in GD patients after COVID-19. Participants will have regular follow-upfor one year to hyperthyroidism in our hospital, and the investigators will collect the thyroid function and related examination indexes of patients in the corresponding time period.
Longitudinal analysis of GD status was performed: Three follow-up time points were identified: before COVID-19, three months and one year after recovering from COVID-19 (the first follow-up visit, the second follow-up visit. Main collection items: Hyperthyroidism symptoms, signs, hyperthyroidism complications, psychological evaluation results, other complications，blood routine, liver and kidney function, thyroid function (FT3, FT4, TSH), thyroid-related antibodies, glucose and lipid metabolism (FBG, HbA1c, TC, TG, HDL-C, LDL-C), thyroid ultrasound and hyperthyroidism medication.Through this to understand the changes of hyperthyroidism in HT patients complicated with COVID-19 and the changes of anxiety and depression in hyperthyroidism patients before and after SARS-CoV-2 infection.And the effect of psychological intervention in GD patients after COVID-19.
Study Type
OBSERVATIONAL
Enrollment
120
The following indicators were collected from these patients: hyperthyroidism symptoms, signs, hyperthyroidism complications, psychological evaluation results, other complications，blood routine, liver and kidney function, thyroid function (FT3, FT4, TSH), thyroid-related antibodies, glucose and lipid metabolism (FBG, HbA1c, TC, TG, HDL-C, LDL-C), thyroid ultrasound and hyperthyroidism medication. Psychological evaluations (using the 7-item Generalized Anxiety Disorder Questionnaire, GAD-7, and the Patient Health Questionnaire 9, PHQ-9) and interventions.
Qilu Hospital of Shandong University
Jinan, Shandong, China
RECRUITINGSerum TSH were measured with chemiluminescence method.
TSH in µIU/mL
Time frame: Up to 9 months
Serum FT4 were measured with chemiluminescence method.
FT4 in pmmol/L
Time frame: Up to 9 months
Serum FT3were measured with chemiluminescence method.
FT3 in pmmol/L
Time frame: Up to 9 months
Serum TRAb were measured with chemiluminescence method.
TRAb in IU/L
Time frame: Up to 9 months
Serum TPO-Ab were measured with chemiluminescence method.
TPO-Ab in IU/ml
Time frame: Up to 9 months
Serum TTG-Ab were measured with chemiluminescence method.
TG-Ab in IU/ml
Time frame: Up to 9 months
Assess the changes of patients' psychological state with Generalized Anxiety Disorder-7 Items Scale（GAD-7)
Evaluation of anxiety state by GAD-7 scale. The lowest score of DAD-7 is 0, and the highest score is 21. The higher the score, the heavier the anxiety.
Time frame: Up to 9 months
Assess the changes of patients' psychological state with Patient Health Questionnaire-9（PHQ-9）
Evaluation of depression by PHQ-9 scale. The lowest score of PHQ-9 is 0, and the highest score is 27. The higher the score, the heavier the depression.
Time frame: Up to 9 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.